Browse Biomarkers Based on Source

This page shows data for Urine source.
Total Entries Retrieved: 170
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
97 Thymosin b15 (Tb15) Protein Humans Upregulated in PCa Diagnostic Untreated Prostate Cancer Vs Controls p<0.001 Urine 15666387
98 Thymosin b15 (Tb15) Protein Humans Upregulated in PCa Diagnostic ADT treated Prostate Cancer Vs Controls p=0.001 Urine 15666387
113 PCaP Polypeptide Panel (PCAPP) Protein Humans Differentially Expressed in Prostate Cancer Diagnostic Prostate Cancer Vs Healthy Controls p<0.05 Urine 19759844
117 ααCTX Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
118 ββCTX Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
119 NTx Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
134 Fusion Status of TMPRSS2-ERG mRNA Humans Fusion of the genes in Positive Biopsy PCa Prognostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
135 PCA3 mRNA Humans Upregulated in Positive Biopsy PCa Prognostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
136 Fusion Status of (TMPRSS2-ERG)+PCA3 mRNA Humans Fused/ Upregulated in PCa Diagnostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
243 SPINK1 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Prostate Cancer p=0.0002 Urine 18245462
244 GOLPH2 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=0.0002 Urine 18245462
245 PCA3 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=0.001 Urine 18245462
246 SPINK1, PCA3, GOLPH2, TMPRSS2:ERG mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=1.91E-11 Urine 18245462
247 SPINK1, PCA3, GOLPH2, TMPRSS2:ERG mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=1.91E-11 Urine 18245462
414 4-OHE1(E2)-1-N7Gua Metabolites Humans Upregulated (PCA median: 0.7pmol/ml vs Control median: 0.3pmol/ml) Diagnostic Prostate Cancer Vs Controls p=0.0004 Urine 18816637
415 4-OHE1-1-N3Ade Metabolites Humans Upregulated (PCA median: 0.4pmol/ml vs Control median: 0.2pmol/ml) Diagnostic Prostate Cancer Vs Controls p=0.056 Urine 18816637
416 2-OHE1-6-N3Ade Metabolites Humans Upregulated (PCA median: 0.2pmol/ml vs Control median: 0pmol/ml) Diagnostic Prostate Cancer Vs Controls p=0.0014 Urine 18816637
444 Differential display 3 (DD3/PCA3) mRNA Humans Upregulated in PCa (37 fold) Diagnostic Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) p=0.0001 Urine 19489685
445 Urinary PSA mRNA Humans Upregulated Diagnostic Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) p=0.0001 Urine 19489685
446 DD3 +PSA mRNA Humans Upregulated Diagnostic Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) p<0.0001 Urine 19489685
484 PSA+MMP-2+ AMACR + Methylation Status of (GSTP1 or RASSF1A) Protein + DNA Humans Upregulated and Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Tumor p=0.036 Urine and Serum 20632177
485 Methylation Status of GSTP1 or RASSF1A Methylation Humans HyperMethylated in PCa Diagnostic Prostate Cancer Vs No Tumor p<0.05 Urine 20632177
486 PSGR (Prostate-Specific G-protein Coupled Receptor) mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer p=0.008 Urine 20672322
487 PCA3 (Prostate Cancer Gene 3) mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer p<0.001 Urine 20672322
488 PSGR + PCA3 mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer NA Urine 20672322
489 PCA3 (Prostate Cancer Gene 3) mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
490 Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
491 Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
510 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in Metastatis Diagnostic Healthy Vs Metastatic p<0.0001 Urine 20043080
543 PCA3 mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0; Multivariate: p=0.02 Urine 20957673
544 TMPRSS2: ERG mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0.002; Multivariate: p=0.028 Urine 20957673
545 Annexin A3 Protein Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0; Multivariate: p=0.027 Urine 20957673
546 Sarcosine Metabolites Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0.011; Multivariate: p=0.015 Urine 20957673
547 PCA3 mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0; Multivariate: p=0.02 Urine 20957673
548 TMPRSS2: ERG mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.002; Multivariate: p=0.028 Urine 20957673
549 Annexin A3 Protein Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.002; Multivariate: p=0.027 Urine 20957673
550 Sarcosine Metabolites Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.011; Multivariate: p=0.015 Urine 20957673
598 Engrailed-2 (EN2) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p<0.0001 Urine 21364037
644 PSMA mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign p=0.016 Urine 21520154
645 PSGR mRNA Humans Upregulted in PCa Diagnostic Prostate Cancer Vs Benign p<0.001 Urine 21520154
646 PCA3 mRNA Humans Upregulted in PCa Diagnostic Prostate Cancer Vs Benign p=0.018 Urine 21520154
647 PSMA + PSGR + PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign NA Urine 21520154
648 PSMA + PSGR + PCA3 + PSA mRNA Humans Differentially Expressed Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml NA Urine 21520154
649 PSMA mRNA Humans Downregulated in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p=0.003 Urine 21520154
650 PSGR mRNA Humans Upregulted in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p= 0.009 Urine 21520154
651 PCA3 mRNA Humans Upregulted in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p=0.025 Urine 21520154
652 PSMA + PSGR + PCA3 mRNA Humans Differentially Expressed Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml NA Urine 21520154
658 PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer p=0.001 Urine 21600800
659 PSA mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate cancer p=0.019 Urine 21600800
660 TMPRSS2:ERG mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer p=0.001 Urine 21600800
661 PSA +PCA3 + TMPRSS2:ERG mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer NA Urine 21600800
662 TMPRSS2:ERG+ PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer NA Urine 21600800
663 Propenoic acid+ Pyrimidine+ Dihyroxybutanoic acid+Creatinine+ Purine+ Glucopyranoside+ Ribofuranoside+Xylonic acid=Xylopyranose Metabolites Humans Upregulated in PCA: (Propenoic acid, Dihyroxybutanoic acid, Creatinine and Xylonic acid); Downregulated in PCA: (Pyrimidine, Creatinine, Purine, Glucopyranoside, Ribofuranoside, Xylopyranose) Diagnostic Prostate Cancer Vs Healthy Men p<0.05 Urine 21626193
664 Dihyroxybutanoic acid + Pyrimidine + Xylonic acid + Xylopyranose + Ribofuranoside Metabolites Humans Upregulated in PCA: (Dihyroxybutanoic acid, Xylonic acid); Downregulated in PCA: (Pyrimidine, Xylopyranose, Ribofuranoside) Diagnostic PCa Vs Non Cancerous (healthy+BPH) p<0.05 Urine 21626193
688 PCA3 mRNA Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
689 PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.04 Urine 21788966
690 AMACR mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.04 Urine 21788966
691 Multiplex Model (PCA3+ AMACR+ SPINK1+ EZH2+ GOLM1+ TRPM8 + MSMB + Serum PSA) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
692 Quadriplex Model (TRPM8 + MSMB+ PCA3+ AMACR) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
693 Triplex Model (TRPM8 + MSMB+AMACR) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
694 Duplex Model (TRPM8 + MSMB) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.01 Urine 21788966
695 AMACR mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.044 Urine 21788966
696 EZH2 mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.022 Urine 21788966
697 EZH2 mRNA Humans Upregulated in Intermediate and further upregulated in High Risk Group Prognostic Low Vs Intermediate Vs High Risk Group High vs low-risk group patients (P = 0.002), intermediate vs low risk group patients (P = 0.044) Urine 21788966
702 Methylation Status of (RARB or GSTP1 or RASSF1) Methylation Humans Hypermethylated in Cancer Prognostic Methylation in Patients with PCa NA Urine 21822036
704 Methylation Status of RARB Methylation Humans Hypermethylated in Gleason Score 7 (PMR>=50) Prognostic Gleason Score 6 Vs Gleason Score 7 p=0.01 Urine 21822036
833 APOD; C1QTNF3; CD27; CFB; CFH; CLU; CRABP1; DDAH2; FTL; IGSF8; ITIH4l; LGALS3; LYZ; MGAT5; PECAM1; RBP4; RECK; SELENBP1; SLIT2; mRNA Humans (1.358 fold) Upregulated in PCa [APOD (2.803 fold) ; C1QTNF3 (1.100 fold); CD27 (1.183 fold); CFB (3.231 fold); CFH (1.381 fold); CLU (1.638 fold); CRABP1 (1.477 fold) ; DDAH2 (1.152 fold) ; FTL (1.718 fold); IGSF8 (1.358 fold) ; ITIH4l (1.215 fold) ; LGALS3 (4.121 fold) ; LYZ (2.093 fold) ; MGAT5 (1.112 fold); PECAM1 (2.404 fold) ; RBP4 (1.872 fold); RECK (2.569 fold) ; SELENBP1 (1.327 fold) ; SLIT2 (1.848 fold)] Diagnostic Prostate Cancer Vs Normal controls p<0.001 Urine 22194848
840 miRNA - 107 miRNA Humans Upregulated in Pca Diagnostic Benign Vs Prostate Cancer p=0.001 Urine 22240788
841 miRNA - 574-3p miRNA Humans Upregulated in PCa Diagnostic Benign Vs Prostate Cancer p=0.012 Urine 22240788
906 Fusion status of TMPRSS2-ERG and TERT expression mRNA Humans TMPRSS2–ERG and TERT-negative tumors had significantly lower rate of recurrence Prognostic Biochemical Recurrence Free Survival p=0.025 Urine 22505341
910 PCA3 Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group p< 0.001 Urine 22542564
918 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group A] NA Urine 22564540
919 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group B] NA Urine 22564540
962 Prostate Cancer Antigen 3 (PCA3) mRNA Humans Upregulated in PCa [No PCa: 32 (13.5–68) Vs PCa 50 (34–83)] Diagnostic PCa Vs No-PCa p=0.001 Urine 22821756
963 PCA3 + phi mRNA Humans Upregulated in PCa Diagnostic PCa Vs No-PCa p=0.001 Urine + Serum 22821756
988 Zinc α2-glycoprotein (ZAG) Protein Humans Upregulated in PCa Diagnostic PCA VS No PCA group p=0.05 Urine 23020913
989 Zinc α2-glycoprotein (ZAG) + PSA Protein Humans Upregulated in PCa Diagnostic PCA VS No PCA group p=0.05 Urine + Serum 23020913
1020 PCA3 score >= 25 mRNA Humans PCA3 Score upregulated in PCa (No PCa: 24; Pca: 60) Diagnostic PCa Vs No PCA group p<0.001 Urine 23201468
1021 TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 mRNA Humans TMPRSS2-ERG fusion upregulated in PCa (No PCa: 15; Pca: 46) Diagnostic PCa Vs No PCA group p<0.001 Urine 23201468
1022 TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p<0.001 Urine 23201468
1023 TMPRSS2-ERG mRNA Humans NA Prognostic Tumor Stage (T3-T4) p = 0.023 Urine 23201468
1068 AMBP precursor (AMBPf1) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.005 Urine 23417432
1069 AMBP precursor (AMBPf2) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.004 Urine 23417432
1070 Saposin Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.002 Urine 23417432
1071 AMBP precursor (AMBPf2) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.004 Urine 23417432
1072 Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.006 Urine 23417432
1079 PCA3 mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1080 TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1081 PCA3 + TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1082 PCA3 mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive Vs Negative Biopsy P =0.01 Urine 23515404
1083 TMPRSS2:ERG mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive Vs Negative Biopsy P =0.001 Urine 23515404
1084 PCA3 + TMPRSS2:ERG + PSA mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1175 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No evidence of Maligancy p <0.001 Urine 23861782
1213 Methylation Status of HIST1H4K Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs Normal Prostate p<0.0001 Urine 24065480
1214 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Urine 24080222
1215 PCA3 + Multiparametric MRI Others Humans PCA3 Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Urine + Technique 24080222
1221 β-Microseminoprotein Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Other Prostatic Conditions p = 0.01 Urine 24115268
1222 β-Microseminoprotein + PSA Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Other Prostatic Conditions β-Microseminoprotein: [p = 0.01] Urine 24115268
1229 miR-205 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1230 miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1231 miR-205+ miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1240 Prostate cancer antigen 3 [PCA3] mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer NA Urine 24211598
1241 PCA3 /PSA ratio (PCa antigen 3 [PCA3]) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer NA Urine 24211598
1247 Anterior gradient 2 [AGR2] Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p = 0.026 Urine 24251762
1251 Active Hepatocyte Growth Factor [aHGF] Protein Humans Upregulated in PCa: [Controls: 111.3; Localised PCa: 235.2] Diagnostic Prostate Cancer Vs No Prostate Cancer p = 0.003 Urine 24266816
1252 Insulin Like Growth Factor Binding Protein 3 (IGFBP3) Protein Humans Upregulated in PCa: [Controls: 0.648; Localised PCa: 0.8862] Diagnostic Prostate Cancer Vs No Prostate Cancer p = 0.003 Urine 24266816
1253 Osteopontin (OPN) Protein Humans Upregulated in PCa: [Localised PCa: 613.6; Metastaic PCa: 1024] Prognostic Localised Vs Metastatic Prostate Cancer p = 0.003 Urine 24266816
1272 Integrin α3 [ITGA3] Protein Humans Upregulated in Metastatic Prostate Cancer Diagnostic Metastasis Vs Prostate Cancer and BPH p<0.005 Urine 24371517
1273 Integrin β1 [ITGB1] Protein Humans Upregulated in Metastatic Prostate Cancer Diagnostic Metastasis Vs Prostate Cancer and BPH p<0.01 Urine 24371517
1327 Human Serum Albumin Complexed with Myristate and Aspirin; Apolipoprotein-D; Prostaglandin H2 D-isomerase; Ig A1 Bur; G-protein coupled receptor 115; Cadherin-1; α-N-acetylglucosaminidase; Pro-epidermal growth factor; Apolipoprotein-J precursor; Human Beta-Defensin-1; Matrilin-4; CD14 antigen; Chemo- kine-like factor superfamily-5 isoform a; Fibronectin precursor; Immunoglobulin-kappa light chain varia- ble region; SLURP1. Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1328 Cadherin -1 Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1329 Fibronectin Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1330 TP53INP2 Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1331 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine + Plasma 24512523
1332 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Urine + Plasma 24512523
1339 miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-483-5p; miR-486-3p; miR-563; miR-940; miRNA Humans Downregulated in PCa: miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-486-3p; miR-563; miR-940; Upregulated in PCa: miR-483-5p Diagnostic Prostate Cancer Vs Healthy Controls p<0.01 Urine 24563673
1340 miR-1825 miRNA Humans Downregulated in PCa vs BPH vs Healthy Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1341 miR-484 miRNA Humans Downregulated in PCa vs BPH vs Healthy Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1342 miR-1825 + miR-484 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1343 miR-1825 + miR-484 + PSA miRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1426 PCA3 mRNA Humans Upregulated in PCa Diagnostic Negative Vs Positive Biopsy for PCa p<0.0001 Urine 24803095
1427 PCA3 mRNA Humans Upregulated in PCa Diagnostic Controls Vs Positive Biopsy for PCa p <0.0001 Urine 24803095
1538 C-Terminal Fragment of PSA Protein Humans Upregulated in PCa (PCa: 117; Non PCa: 36.8) Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.0016 Urine 25233230
1541 Anterior gradient 2 Wild Type (AGR2wt) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.001 Urine 25237833
1542 Anterior gradient 2 Slice Variant C (AGR2-SV-C) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1543 Anterior gradient 2 Slice Variant E (AGR2-SV-E) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.01 Urine 25237833
1544 Anterior gradient 2 Slice Variant F (AGR2-SV-F) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.01 Urine 25237833
1545 Anterior gradient 2 Slice Variant G (AGR2-SV-G) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1546 Anterior gradient 2 Slice Variant H (AGR2-SV-H) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1590 AK024556; XLOC_007697; LOC100287482; XLOC_005327; XLOC_008559; XLOC_009911; LncRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Urine 25307116
1592 miRNA-483-5p miRNA Humans Upregulated in PCa Diagnostic Benign Vs Malignant p=0.013 Urine 25445383
1593 miRNA-483-5p+ PSA miRNA Humans Upregulated in PCa Diagnostic Benign Vs Malignant p=0.013 Urine 25445383
1694 TTTY15-USP9Y mRNA Humans Upregulated in PCa Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1695 TTTY15-USP9Y + PSA mRNA Humans Downregulated in Gleason Pattern 4 and 5 Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1696 TTTY15-USP9Y mRNA Humans Downregulated in Gleason Upgrade Patients Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1697 hsa-miR-518a miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1698 hsa-miR-3605 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.033 Urine 26126436
1699 hsa-miR-16 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.04 Urine 26126436
1700 RUN6-2 miRNA Humans Downregulated in PCa (BPH: 4098.6; PCa: 2670.6) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1701 hsa-miR-615-3p miRNA Humans Downregulated in PCa (BPH: 8842.4; PCa: 2781.7) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1702 hsv1-miR-H18 miRNA Humans Downregulated in PCa (BPH: 1030.7; PCa: 619.2) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1703 hsv2-miR-H9-5p miRNA Humans Downregulated in PCa (BPH: 1030.7; PCa: 619.2) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1704 hsv1-miR-H18 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.004 Tissue+Urine+Serum 26126436
1705 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.002 Tissue+Urine+Serum 26126436
1706 hsa-miR-615-3p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1707 hsa-miR-BARTA-4 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1708 hsa-miR-4316 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Urine: p=0.022 Tissue+Urine+Serum 26126436
1709 hsv1-miR-H18 miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1710 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1724 CRIP3 Methylation Humans Upregulated in PCa Prognostic Reclassification (Progression Vs No Progression) p=0.017 Urine 30777394
1725 miR-24+miR-30c+ Methylation Status of CRIP3 miRNA + DNA (Gene) Humans Increased in shorter BCR-free survival Prognostic Reclassification (Progression Vs No Progression) Univariate: p=0.008; Multivariate: p=0.017 Urine 30777394
1813 APC; HOXD3; TGFβ2; GSTP1; KLK10 Methylation Humans NA Diagnostic Prostate Cancer Vs Benign p<0.05 Urine 30470249
1814 APC Methylation Humans NA Diagnostic Benign Vs High CAPRA Score p<0.01 Urine 30470249
1815 HOXD3 Methylation Humans NA Diagnostic Benign Vs High CAPRA Score p<0.01 Urine 30470249
1816 TGFβ2 Methylation Humans Methylated in PCa Diagnostic Benign Vs High CAPRA Score p<0.05 Urine 30470249
1817 GSTP1 Methylation Humans Methylated in PCa Diagnostic Benign Vs High CAPRA Score p<0.01 Urine 30470249
1818 KLK10 Methylation Humans Methylated in PCa Diagnostic Benign Vs High CAPRA Score p<0.001 Urine 30470249
1819 TBX15 Methylation Humans Methylated in PCa Diagnostic Benign Vs High CAPRA Score p<0.05 Urine 30470249
1820 HOXD3+GSTP1 Methylation Humans Methylated in PCa Diagnostic Benign Vs High CAPRA Score p<0.001 Urine 30470249
1821 AMBP; (cDNA FLJ50830, highly similar to AMBP); (unnamed protein product); (Isoform 2 of Calmodulin-regulated spectrin-associated protein 1-like 1 (CAMSAP1L1); cDNA FLJ51445, highlysimilar to AMBP protein; Ribosomal RNA upstream binding transcription factor (Fragment, UBTF); Basementmembrane-specific heparan sulfate proteoglycan coreprotein (HSPG2); Ferritin heavy chain (FTH1); Transthyretin; 13 kDa protein; Unknown (protein for IMAGE:3934797); Putative beta-actin-like protein 3 F7 Factor VII active sitemutant immunoconjugate; C11orf54 Aminoacylase-1 (ACY1); Ferritin Light chain (FTL) Coactosin-like protein (COTL1); Protein Humans Methylated in PCa Diagnostic Prostate Cancer Vs Controls and Benign Prostatic Hyperplasia p<0.05 Urine 30610587
1849 miR-30c-5p miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1850 miR- 222-3p*+ miR-24-3p+ miR-30c-5p miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1851 miR- 222-3p*+ miR-24-3p+ miR-30c-5p+PSA miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1858 PDGF-BB (Platelet Derived Growth Factor-BB) Protein Humans Upregulated in Recurrent PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.04 Urine 30374275
1859 PDGF-BB/Cr (Platelet Derived Growth Factor-BB/creatinine) Protein Humans Upregulated in Recurrent PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.016 Urine 30374275
1862 Promoter methylation of: miR-193b+ miR-34b/c Methylation Humans Upregulated in PCa (Non PCa: 1504.7 Vs PCa: 1657.1) Diagnostic Prostate Cancer Vs Controls p<0.05 Urine 30373654
1863 Methlyation Status of APC, GSTP1 RARβ2 Methylation Humans Methylated in PCa Diagnostic Prostate Cancer Vs Controls p<0.05 Urine 30373654
1864 Methlyation Status of APC, GSTP1 RARβ2 Methylation Humans Methylated in PCa Diagnostic Prostate Cancer Vs Controls p<0.05 Urine 30373654
1875 KNG1 (Kininogen-1); Protein Humans Methylated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p<0.05 Urine 30237853
1888 4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; 1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone Metabolites Humans Downregulated in PCa [SCO‐spondin (0.1 fold); Complement component C7 (0.1‐fold); Isoform 2 of Ankyrin repeat and SOCS box protein 18 (0.3‐fold); Gelsolin (0.3‐fold); Serum amyloid P-component (0.4‐fold); Ig heavy chain V‐I region V35 (0.5‐fold); Complement C1q subcomponent subunit C (0.5‐fold); Complement component C8 alpha chain (0.6‐fold); Isoform 2 of Filamin A (0.6‐fold); and Inter-alpha-trypsin inhibitor heavy chain H2 (0.7‐fold);] Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.05 Urine 30853355